Atlantic Fish, an emerging Raleigh company developing cultivated seafood, has received a $50,000 SEED grant from North ...

The post-award management of NCBiotech grants and loans is administered NCBiotech's Contracts and Grants Department. If you have questions related to budget changes, project extensions, reporting or ...

North Carolina is a global leader in gene therapy thanks to its renowned life science workforce development programs and the scientific output of its research universities. For example, Pfizer’s first ...

Norris Tolson, President and CEO of the North Carolina Biotechnology Center, today announced that he will be stepping down, effective June 30. The NCBiotech Board of Directors will begin a search for ...

More than a decade ago, University of North Carolina at Chapel Hill scientist Anne Taylor, Ph.D., then a bioengineering graduate student at the University of California at Irvine, determined she ...

Istari Oncology, a young Research Triangle Park biotechnology company started by a world-famous Duke University brain cancer team, has reported rare positive results in a Phase 1 clinical trial of its ...

Seqirus, already the world’s largest producer of cell-based influenza vaccines, is about to grow even larger due to strong global demand for its quadrivalent flu vaccine. The company broke ground this ...

The North Carolina One Health Collaborative seeks to promote and improve the health and well-being of all species by enhancing collaboration among physicians, veterinarians, researchers, and other ...

Fervent Pharmaceuticals of Greenville has successfully submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for FP-101, its proprietary lead drug candidate ...

Fresenius Kabi will expand its drug-manufacturing operations in Wilson, potentially bringing at least 445 new jobs over five years and $100 million in investment. The German company will enlarge its ...

Asklepios BioPharmaceutical (AskBio), a gene therapy platform company based in Chapel Hill, has spun out its fourth company, Actus Therapeutics, to develop gene therapies for rare genetic diseases ...